Impact of dabigatran on platelet function and fibrinolysis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F15%3A00063324" target="_blank" >RIV/00159816:_____/15:00063324 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jns.2015.07.031" target="_blank" >http://dx.doi.org/10.1016/j.jns.2015.07.031</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jns.2015.07.031" target="_blank" >10.1016/j.jns.2015.07.031</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of dabigatran on platelet function and fibrinolysis

Popis výsledku v původním jazyce

Background: We sought to evaluate the potential enhanced fibrinolytic and antiplatelet activity of dabigatran etexilate (DE) due to decreased thrombin levels in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation (NVAF). Methods: Consecutive patients with cerebrovascular diseases and NVAF that were treated with DE in a tertiary university hospital. Fibrinolysis and platelet function were assessed by thromboelastometry (ROTEM) and platelet function analyzer (PFA)-100, respectively, before and after treatment with DE. Conventional coagulation tests, endogenous thrombin potential (ETP) and hemoclot thrombin inhibitors (HTI), were also performed in order to detect any possible correlation between dabigatran plasma levels,its anticoagulant activity and the intensity of platelet dysfunction or fibrinolysis. Results: A total of nineteen patients fulfilled our inclusion criteria (mean age 623 +/- 7.2 years; 47% males; median CHADS2-score: 3; interquartile ra

Název v anglickém jazyce

Impact of dabigatran on platelet function and fibrinolysis

Popis výsledku anglicky

Background: We sought to evaluate the potential enhanced fibrinolytic and antiplatelet activity of dabigatran etexilate (DE) due to decreased thrombin levels in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation (NVAF). Methods: Consecutive patients with cerebrovascular diseases and NVAF that were treated with DE in a tertiary university hospital. Fibrinolysis and platelet function were assessed by thromboelastometry (ROTEM) and platelet function analyzer (PFA)-100, respectively, before and after treatment with DE. Conventional coagulation tests, endogenous thrombin potential (ETP) and hemoclot thrombin inhibitors (HTI), were also performed in order to detect any possible correlation between dabigatran plasma levels,its anticoagulant activity and the intensity of platelet dysfunction or fibrinolysis. Results: A total of nineteen patients fulfilled our inclusion criteria (mean age 623 +/- 7.2 years; 47% males; median CHADS2-score: 3; interquartile ra

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.100%2F02%2F0123" target="_blank" >ED1.100/02/0123: Fakultní nemocnice u sv. Anny v Brně - Mezinárodní centrum klinického výzkumu (FNUSA - ICRC)</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the Neurological Sciences

ISSN

0022-510X

e-ISSN

—

Svazek periodika

357

Číslo periodika v rámci svazku

1-2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

204-208

Kód UT WoS článku

000362138800034

EID výsledku v databázi Scopus

—